Researchers are increasingly focused on retatrutide, a innovative treatment developed by Eli Lilly, as a significant step in body reduction . Different than many earlier approaches, retatrutide is a dual -action agonist targeting both GLP-1 and GIP, hormones that impact satiety and blood sugar co